Aptevo Therapeutics (APVO) Research & Development (2015 - 2026)
Aptevo Therapeutics (APVO) posted Research & Development of $3.9 million for Q1 2026, up 11.0% sequentially from $3.5 million in Q4 2025, and up 8.01% YoY from $3.6 million in Q1 2025.
Aptevo Therapeutics (APVO) Research & Development (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Research & Development for 12 years, with the latest figure at $3.9 million in Q1 2026.
- Quarterly Research & Development rose 8.01% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.8 million (up 4.01% YoY) and the FY2025 annual result came in at $14.5 million, up 1.13% from the prior year.
- Research & Development rose to $3.9 million in Q1 2026 per APVO's latest filing, from $3.5 million in the prior quarter.
- Over five years, Research & Development peaked at $5.5 million in Q2 2023 and troughed at $3.1 million in Q3 2024.
- A 5-year average of $4.0 million and a median of $3.9 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development jumped 41.32% in 2023, then plunged 33.3% in 2024.
- Over 5 years, Research & Development stood at $4.7 million in 2022, then declined by 23.17% to $3.6 million in 2023, then climbed by 8.05% to $3.9 million in 2024, then fell by 8.89% to $3.5 million in 2025, then grew by 11.0% to $3.9 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $3.9 million, $3.5 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Aptevo Therapeutics | 3.30 Mn | -6.50 Mn | - | 3.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.70 Mn |
| Mar 31, 2026 | 3.92 Mn |
| Dec 31, 2025 | 3.54 Mn |
| Sep 30, 2025 | 4.04 Mn |
| Jun 30, 2025 | 3.33 Mn |
| Mar 31, 2025 | 3.63 Mn |
| Dec 31, 2024 | 3.88 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 3.64 Mn |
| Mar 31, 2024 | 3.75 Mn |
| Dec 31, 2023 | 3.59 Mn |
| Sep 30, 2023 | 3.89 Mn |
| Jun 30, 2023 | 5.46 Mn |
| Mar 31, 2023 | 4.17 Mn |
| Dec 31, 2022 | 4.67 Mn |
| Sep 30, 2022 | 4.48 Mn |
| Jun 30, 2022 | 3.87 Mn |
| Mar 31, 2022 | 4.87 Mn |
| Dec 31, 2021 | 4.54 Mn |
| Sep 30, 2021 | 4.37 Mn |